Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Anavex Life Sciences Corp. (NASDAQ: AVXL).

Full DD Report for AVXL

You must become a subscriber to view this report.


Recent News from (NASDAQ: AVXL)

Anavex Life Sciences to Announce 2018 Fiscal Year End Financial Results on Wednesday, December 12, 2018
NEW YORK, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental dise...
Source: GlobeNewswire
Date: December, 10 2018 07:00
Alzheimer's Pathways: An Investor's Guide To Biogen, Anavex, And Neurotrope
At the recent CTAD conference in Barcelona, Spain a number of companies presented new data regarding their Alzheimer’s drug candidates. Much of the attention focused on Biogen ( BIIB ), but other companies may be pursuing more fruitful strategies against Alzheimer’s disease. In...
Source: SeekingAlpha
Date: November, 06 2018 10:42
Report: Developing Opportunities within Stryker, Anavex Life Sciences, Engility, Baker Hughes, a GE company, GlycoMimetics, and HCP - Future Expectations, Projections Moving into 2018
NEW YORK, Nov. 06, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Stryker Corporation (NYSE:SYK), Anavex Life Sciences Corp. (NASDAQ:AVXL),...
Source: GlobeNewswire
Date: November, 06 2018 07:40
First Patient Enrolled in Anavex Life Sciences Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Parkinson's Disease Dementia (PDD)
Study will incorporate genomic precision medicine ANAVEX®2-73-specific biomarkers NEW YORK, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing di...
Source: GlobeNewswire
Date: October, 30 2018 07:00
First Patient Enrolled in Anavex Life Sciences Phase 2b/3 Clinical Trial of ANAVEX®2-73 for the Treatment of Early Alzheimer's Disease
ANAVEX®2-73 Being Studied as Potential First Precision Medicine Biomarker-guided, Targeted Therapeutic in Alzheimer’s Disease Primary and Secondary Endpoints measuring Safety, and Cognitive and Functional Efficacy (ADAS-Cog, ADCS-ADL and CDR-SB) NEW YORK, Aug. 28, 2018 (GLO...
Source: GlobeNewswire
Date: August, 28 2018 07:00
Investor Expectations to Drive Momentum within Capital Senior Living, Thermon Group, L.B. Foster, Anavex Life Sciences, Opiant Pharmaceuticals, and Huron Consulting Group - Discovering Underlying Factors of Influence
NEW YORK, Aug. 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Capital Senior Living Corporation (NYSE:CSU), Thermon Group Holdings, Inc...
Source: GlobeNewswire
Date: August, 16 2018 07:55
Anavex Life Sciences' (AVXL) CEO Christopher Missling on Q3 2018 Results - Earnings Call Transcript
Anavex Life Sciences Corp (AVXL) Q3 2018 Earnings Conference Call August 9, 2018 4:30 PM ET Executives Scott Gordon – Investor Relations Christopher Missling – President and Chief Executive Officer Sandra Boenisch – Principal Financial Officer Analysts ...
Source: SeekingAlpha
Date: August, 09 2018 21:55
Anavex Life Sciences Reports Fiscal Third Quarter 2018 Financial Results
Conference Call and Webcast Today at 4:30 p.m. ET NEW YORK, Aug. 09, 2018 (GLOBE NEWSWIRE) --  Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the...
Source: GlobeNewswire
Date: August, 09 2018 07:00
Anavex Life Sciences to Announce Fiscal Third Quarter 2018 Financial Results on Thursday, August 9, 2018
Conference Call and Webcast To be Held Thursday, August 9, 2018 at 4:30pm Eastern time NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp., (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing d...
Source: GlobeNewswire
Date: August, 07 2018 07:00
Investor Expectations to Drive Momentum within NetApp, eBay, The Boeing, HCP, Atossa Genetics, and Anavex Life Sciences - Discovering Underlying Factors of Influence
NEW YORK, July 30, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of NetApp, Inc. (NASDAQ:NTAP), eBay Inc. (NASDAQ:EBAY), The Boeing Company (...
Source: GlobeNewswire
Date: July, 30 2018 08:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-171.981.88962.011.88347,782
2018-12-142.032.0052.06991.98251,758
2018-12-132.072.0252.12332.01234,035
2018-12-122.112.132.192.11139,017
2018-12-112.122.11382.21522.09151,444

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1765,774150,11843.8149Short
2018-12-1455,608115,52648.1346Short
2018-12-1338,91782,61847.1047Short
2018-12-1226,18771,18236.7888Short
2018-12-1115,83684,35118.7739Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AVXL.


About Anavex Life Sciences Corp. (NASDAQ: AVXL)

Logo for Anavex Life Sciences Corp. (NASDAQ: AVXL)

Anavex is a pharmaceutical company engaged in the development of drug candidates.

 

Contact Information

 

 

Current Management

  • Christopher Missling / President, CEO, CFO
  • Christine Payne / IR
  • Sandra Boenisch / Principal Acct. Officer
  • Christopher Missling / Chairman
  • Elliot Favus /
  • Bernd Metzner /
  • Athanasios Skarpelos /
  • Steffen Thomas /

Current Share Structure

  • Market Cap: $119,012,014 - 03/20/2018
  • Authorized: 100,000,000 - 10/07/2015
  • Issue and Outstanding: 44,573,788 - 02/07/2018

 


Recent Filings from (NASDAQ: AVXL)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 20 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 08 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: AVXL)

Daily Technical Chart for (NASDAQ: AVXL)


Stay tuned for daily updates and more on (NASDAQ: AVXL)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: AVXL)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AVXL is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of AVXL and does not buy, sell, or trade any shares of AVXL. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/